OBJECTIVES: To determine the role of systemic complement activation in the pathogenesis of age-related macular degeneration and to examine whether serum C3a des Arg reflects systemic complement activation, independent of individual complement component levels. METHODS: Plasma complement C3a des Arg levels and a single nucleotide polymorphism at position 402 of the complement factor H gene (CFH) were determined in 3 groups of subjects: 42 subjects with early age-related maculopathy, 42 subjects with neovascular (wet) age-related macular degeneration, and a control group of 38 subjects with no clinical evidence of age-related changes at the macula. RESULTS: The median (range) of plasma complement C3a des Arg levels in the age-related maculopathy and neovascular age-related macular degeneration groups were 52.6 (2.8-198.1) ng/mL and 60.9 (3.1-173.1) ng/mL, respectively. The levels were significantly raised compared with the control group (n = 38), which had a median (range) plasma complement C3a des Arg level of 40.3 (6.1-81.7) ng/mL (analysis of variance, P = .02). The concentration of plasma C3a des Arg did not differ significantly between those with different CFH genotypes (P = .07). CONCLUSION: Systemic activation of the complement system may contribute to the pathogenesis of age-related macular degeneration independent of CFH polymorphism. CLINICAL RELEVANCE: The results of this study may be relevant to aiming new treatment strategies toward reducing systemic low-grade inflammation.
OBJECTIVES: To determine the role of systemic complement activation in the pathogenesis of age-related macular degeneration and to examine whether serum C3a des Arg reflects systemic complement activation, independent of individual complement component levels. METHODS: Plasma complement C3a des Arg levels and a single nucleotide polymorphism at position 402 of the complement factor H gene (CFH) were determined in 3 groups of subjects: 42 subjects with early age-related maculopathy, 42 subjects with neovascular (wet) age-related macular degeneration, and a control group of 38 subjects with no clinical evidence of age-related changes at the macula. RESULTS: The median (range) of plasma complement C3a des Arg levels in the age-related maculopathy and neovascular age-related macular degeneration groups were 52.6 (2.8-198.1) ng/mL and 60.9 (3.1-173.1) ng/mL, respectively. The levels were significantly raised compared with the control group (n = 38), which had a median (range) plasma complement C3a des Arg level of 40.3 (6.1-81.7) ng/mL (analysis of variance, P = .02). The concentration of plasma C3a des Arg did not differ significantly between those with different CFH genotypes (P = .07). CONCLUSION: Systemic activation of the complement system may contribute to the pathogenesis of age-related macular degeneration independent of CFH polymorphism. CLINICAL RELEVANCE: The results of this study may be relevant to aiming new treatment strategies toward reducing systemic low-grade inflammation.
Authors: Tamara Montes; Agustín Tortajada; B Paul Morgan; Santiago Rodríguez de Córdoba; Claire L Harris Journal: Proc Natl Acad Sci U S A Date: 2009-03-02 Impact factor: 11.205
Authors: Robert F Mullins; Aaron D Dewald; Luan M Streb; Kai Wang; Markus H Kuehn; Edwin M Stone Journal: Exp Eye Res Date: 2011-06-26 Impact factor: 3.467
Authors: Robyn Reynolds; M Elizabeth Hartnett; John P Atkinson; Patricia C Giclas; Bernard Rosner; Johanna M Seddon Journal: Invest Ophthalmol Vis Sci Date: 2009-08-06 Impact factor: 4.799
Authors: Peter J Coffey; Carlos Gias; Caroline J McDermott; Peter Lundh; Matthew C Pickering; Charanjit Sethi; Alan Bird; Fred W Fitzke; Annelie Maass; Li Li Chen; Graham E Holder; Philip J Luthert; Thomas E Salt; Stephen E Moss; John Greenwood Journal: Proc Natl Acad Sci U S A Date: 2007-10-05 Impact factor: 11.205
Authors: Carsten Faber; Jennifer Williams; Helene Bæk Juel; John Greenwood; Mogens Holst Nissen; Stephen E Moss Journal: Invest Ophthalmol Vis Sci Date: 2012-09-19 Impact factor: 4.799